PE20250395A1 - Tratamientos con nirogacestat - Google Patents
Tratamientos con nirogacestatInfo
- Publication number
- PE20250395A1 PE20250395A1 PE2024002630A PE2024002630A PE20250395A1 PE 20250395 A1 PE20250395 A1 PE 20250395A1 PE 2024002630 A PE2024002630 A PE 2024002630A PE 2024002630 A PE2024002630 A PE 2024002630A PE 20250395 A1 PE20250395 A1 PE 20250395A1
- Authority
- PE
- Peru
- Prior art keywords
- nirogacestat
- improved methods
- treatments
- tumors
- gamma
- Prior art date
Links
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 title abstract 3
- 229950001637 nirogacestat Drugs 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 206010059352 Desmoid tumour Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010073260 Ovarian granulosa cell tumour Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000006827 desmoid tumor Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000029749 ovarian granulosa cell tumor Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a metodos mejorados de tratamiento con nirogacestat. Ademas incluye la mejora de metodos de tratar condiciones responsables para inhibir gamma secretasa, tal como tumor desmoide, mieloma multiple, tumores de celulas de la granulosa ovaria, con nirogacestat y sales farmaceuticamente aceptables de este.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263365125P | 2022-05-20 | 2022-05-20 | |
| US202263365193P | 2022-05-23 | 2022-05-23 | |
| PCT/US2023/022881 WO2023225283A1 (en) | 2022-05-20 | 2023-05-19 | Treatments with nirogacestat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250395A1 true PE20250395A1 (es) | 2025-02-11 |
Family
ID=88792609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024002630A PE20250395A1 (es) | 2022-05-20 | 2023-05-19 | Tratamientos con nirogacestat |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US11872211B2 (es) |
| EP (1) | EP4525828A4 (es) |
| JP (1) | JP2025516885A (es) |
| KR (1) | KR20250013187A (es) |
| CN (1) | CN119486713A (es) |
| AU (1) | AU2023271953A1 (es) |
| CA (1) | CA3256695A1 (es) |
| CL (1) | CL2024003511A1 (es) |
| CO (1) | CO2024017497A2 (es) |
| IL (1) | IL316750A (es) |
| MX (1) | MX2024014317A (es) |
| PE (1) | PE20250395A1 (es) |
| WO (1) | WO2023225283A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113924318B (zh) * | 2019-04-10 | 2025-06-20 | 葛兰素史密斯克莱知识产权发展有限公司 | 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法 |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| PE20250395A1 (es) * | 2022-05-20 | 2025-02-11 | Springworks Therapeutics Inc | Tratamientos con nirogacestat |
| US11951096B2 (en) * | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342118B2 (en) | 2004-03-23 | 2008-03-11 | Pfizer Inc | Imidazole compounds for the treatment of neurodegenerative disorders |
| CN113924318B (zh) | 2019-04-10 | 2025-06-20 | 葛兰素史密斯克莱知识产权发展有限公司 | 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法 |
| US10590087B1 (en) * | 2019-08-09 | 2020-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
| WO2021146604A1 (en) * | 2020-01-16 | 2021-07-22 | Allogene Therapeutics, Inc. | Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors |
| IL296075A (en) | 2020-03-13 | 2022-11-01 | Springworks Therapeutics Inc | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
| IL296723A (en) * | 2020-03-26 | 2022-11-01 | Seagen Inc | Methods of treating multiple myeloma |
| TW202327650A (zh) | 2021-09-23 | 2023-07-16 | 美商思進公司 | 治療多發性骨髓瘤之方法 |
| WO2023064872A1 (en) | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| EP4426294A4 (en) | 2021-11-05 | 2025-12-31 | Springworks Therapeutics Inc | Compositions and treatments based on Nirogacestat |
| PE20250395A1 (es) * | 2022-05-20 | 2025-02-11 | Springworks Therapeutics Inc | Tratamientos con nirogacestat |
-
2023
- 2023-05-19 PE PE2024002630A patent/PE20250395A1/es unknown
- 2023-05-19 CN CN202380051358.4A patent/CN119486713A/zh active Pending
- 2023-05-19 CA CA3256695A patent/CA3256695A1/en active Pending
- 2023-05-19 KR KR1020247041680A patent/KR20250013187A/ko active Pending
- 2023-05-19 US US18/320,547 patent/US11872211B2/en active Active
- 2023-05-19 AU AU2023271953A patent/AU2023271953A1/en active Pending
- 2023-05-19 JP JP2024568848A patent/JP2025516885A/ja active Pending
- 2023-05-19 EP EP23808361.2A patent/EP4525828A4/en active Pending
- 2023-05-19 IL IL316750A patent/IL316750A/en unknown
- 2023-05-19 WO PCT/US2023/022881 patent/WO2023225283A1/en not_active Ceased
- 2023-05-19 US US18/320,591 patent/US20230372301A1/en not_active Abandoned
- 2023-07-30 US US18/361,884 patent/US11925619B2/en active Active
- 2023-10-20 US US18/491,283 patent/US11938116B2/en active Active
- 2023-10-20 US US18/491,323 patent/US12011434B2/en active Active
- 2023-10-20 US US18/491,379 patent/US11957662B2/en active Active
- 2023-10-20 US US18/491,225 patent/US11925620B1/en active Active
-
2024
- 2024-11-18 CL CL2024003511A patent/CL2024003511A1/es unknown
- 2024-11-19 MX MX2024014317A patent/MX2024014317A/es unknown
- 2024-12-19 CO CONC2024/0017497A patent/CO2024017497A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119486713A (zh) | 2025-02-18 |
| US20230372301A1 (en) | 2023-11-23 |
| CL2024003511A1 (es) | 2025-04-04 |
| US12011434B2 (en) | 2024-06-18 |
| EP4525828A4 (en) | 2025-10-22 |
| US11872211B2 (en) | 2024-01-16 |
| US20240050411A1 (en) | 2024-02-15 |
| US11925620B1 (en) | 2024-03-12 |
| US11957662B2 (en) | 2024-04-16 |
| KR20250013187A (ko) | 2025-01-31 |
| US20240058305A1 (en) | 2024-02-22 |
| MX2024014317A (es) | 2024-12-06 |
| US20240033251A1 (en) | 2024-02-01 |
| US20240050410A1 (en) | 2024-02-15 |
| US11925619B2 (en) | 2024-03-12 |
| WO2023225283A1 (en) | 2023-11-23 |
| EP4525828A1 (en) | 2025-03-26 |
| IL316750A (en) | 2025-01-01 |
| CA3256695A1 (en) | 2023-11-23 |
| US20240091197A1 (en) | 2024-03-21 |
| JP2025516885A (ja) | 2025-05-30 |
| US20230372300A1 (en) | 2023-11-23 |
| US11938116B2 (en) | 2024-03-26 |
| CO2024017497A2 (es) | 2024-12-30 |
| AU2023271953A1 (en) | 2024-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20250395A1 (es) | Tratamientos con nirogacestat | |
| BR112021020409A2 (pt) | Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase | |
| CL2021002002A1 (es) | Inhibidores de enpp1 y métodos para modular una respuesta inmunitaria. | |
| CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| CO2021009078A2 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
| MX2023001689A (es) | Inhibidores de bcl-2. | |
| MX2022000271A (es) | Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos. | |
| CO2025015814A2 (es) | Inhibidores de kras de 2-azabiciclo [2.2.1] heptano | |
| CL2021002966A1 (es) | Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer. | |
| EA201591610A1 (ru) | Ингибиторы кинуренинового пути | |
| MX2017014584A (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| MX381890B (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| CL2022003511A1 (es) | Inhibidores de alk2 para el tratamiento de la anemia. | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
| WO2021041539A3 (en) | Pyrido-indole analogues as gpx4 inhibitors | |
| CO2024011199A2 (es) | Composiciones y métodos para inhibir el factor b del complemento | |
| PE20241326A1 (es) | Composiciones y tratamientos con nirogacestat | |
| DOP2023000085A (es) | Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados | |
| MX2024013787A (es) | Inhibidores de menina-mll para el tratamiento de cáncer. | |
| CL2023000857A1 (es) | Inhibidores line-1 para tratar la enfermedad | |
| AR119033A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| MX2021015937A (es) | Inhibicion de sirp-gamma para el tratamiento del cancer. | |
| PH12022550585A1 (en) | Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies |